Respiratory Endotherapy Devices Market Report 2026

The respiratory endotherapy devices market size has grown strongly in recent years. It will grow from $3.32 billion in 2025 to $3.54 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to rise in chronic respiratory diseases, growth in lung cancer diagnosis, expansion of interventional pulmonology, hospital endoscopy unit growth, demand for minimally invasive procedures.

The respiratory endotherapy devices market size is expected to see strong growth in the next few years. It will grow to $4.66 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increase in early lung screening programs, robotic bronchoscopy adoption, outpatient pulmonary procedures growth, advanced imaging integration, precision airway therapy demand. Major trends in the forecast period include minimally invasive airway intervention devices, disposable bronchoscope adoption, image guided bronchoscopic procedures, advanced endobronchial ablation systems, smart navigation bronchoscopy tools.

The rising adoption of robotic-assisted bronchoscopy delivery is anticipated to drive the growth of the respiratory endotherapy devices market in the coming years. Robotic-assisted bronchoscopy systems are advanced technologies that enable precise navigation within the respiratory tract, improving diagnostic accuracy and therapeutic outcomes. The demand for these systems is increasing as healthcare providers seek minimally invasive solutions that reduce procedure time, enhance patient safety, and improve clinical efficiency. Respiratory endotherapy devices equipped with robotic assistance support complex interventions by providing real-time imaging, better maneuverability, and enhanced control. For example, in September 2025, according to the European Respiratory Society International Congress, a Switzerland-based membership organization, the use of robotic-assisted bronchoscopy with integrated cone beam CT for peripheral lung lesions has risen to 84.6% in 2025, up from just 23.1% with conventional bronchoscopy in 2024. Therefore, the rising adoption of robotic-assisted bronchoscopy is driving the growth of the respiratory endotherapy devices market.

Companies operating in the respiratory endotherapy devices market are focusing on developing advanced solutions, such as endobronchial valves, to minimize treatment risk while achieving targeted lung volume reduction without permanent tissue removal. An endobronchial valve is a minimally invasive implant placed via bronchoscopy into selected airways to block airflow to diseased lung regions, allowing healthier areas to function more effectively. For example, in February 2024, Olympus Canada Inc., a Canada-based medical technology company, launched the Spiration Valve System for the treatment of severe emphysema. It is an umbrella-shaped device designed to be placed in the most severely diseased lung regions using a minimally invasive bronchoscopic procedure. It uniquely redirects airflow away from hyperinflated lung areas toward healthier tissue, supporting improved respiratory mechanics. As the only endobronchial valve therapy currently available in Canada, it addresses an unmet need in severe emphysema management. Clinical evidence from the EMPROVE trial demonstrates durable benefits through 24 months, including meaningful improvements in lung function, breathlessness, and patient quality of life.

In November 2023, Broncus Medical Inc., a US-based provider of interventional pulmonology devices, acquired Hangzhou Jingliang Medical Technology for an undisclosed amount. Through this acquisition, Broncus Medical aims to enhance its technological capabilities in fiber-optic navigation, flexible catheter systems, and robotic-assisted bronchoscopy, strengthening its product portfolio in respiratory endotherapy and minimally invasive lung procedures. Hangzhou Jingliang Medical Technology is a China-based medical technology company specializing in respiratory endotherapy devices.

Major companies operating in the respiratory endotherapy devices market are Johnson & Johnson, Medtronic plc, Siemens Healthineers, Stryker Corporation, GE Healthcare Technologies Inc., Boston Scientific Corporation, Intuitive Surgical Inc., Olympus Corporation, Hoya Corporation, Steris Healthcare, Teleflex Incorporated, Karl Storz SE & Co. KG, CookMedical, Merit Medical Systems Inc., Ambu A/S, Vygon, Richard Wolf GmbH, Vapotherm Inc, Scholly Fiberoptic GmbH, Clarus Medical LLC, ENDO-FLEX GmbH, The Lung Docs Inc., and Broncus Medical Inc.

Tariffs are impacting the respiratory endotherapy devices market by increasing the cost of imported bronchoscopes, ultrasound systems, catheters, and specialized airway implants. Higher duties on precision medical device components are raising procurement costs for hospitals and ambulatory surgical centers. Regions that rely heavily on imported interventional pulmonology equipment are facing pricing pressure and slower device upgrades. Advanced imaging and ablation device segments are more affected due to their high component value. Smaller care centers are more sensitive to tariff driven price increases. At the same time, tariffs are encouraging regional medical device manufacturing and assembly. This is supporting local suppliers and distribution partnerships.

The respiratory endotherapy devices market research report is one of a series of new reports that provides respiratory endotherapy devices market statistics, including respiratory endotherapy devices industry global market size, regional shares, competitors with a respiratory endotherapy devices market share, detailed respiratory endotherapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory endotherapy devices industry. This respiratory endotherapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Respiratory endotherapy devices are medical tools developed to diagnose and treat respiratory diseases using minimally invasive techniques performed within the airways and lungs. These devices allow visualization, access, and targeted therapeutic delivery inside the respiratory system to manage conditions such as lung cancer, airway blockages, chronic obstructive pulmonary disease, and lung infections. They are designed to enhance patient outcomes by enabling accurate treatment while minimizing the need for open surgery.

The primary product types of respiratory endotherapy devices include bronchoscopes, endobronchial ultrasound systems, biopsy forceps, guidewires, catheters, airway stents, endobronchial valves, ablation devices, and other endotherapy accessories. Bronchoscopes refer to instruments used to visually inspect the airways and conduct therapeutic or diagnostic procedures within the respiratory tract. These devices include diagnostic tools such as transbronchial aspiration instruments, biopsy forceps, cytology brushes, and other diagnostic devices. They are used for patient types including adult patients and pediatric patients. They are utilized by end users including hospitals, diagnostic centers, and ambulatory surgical centers, and are applied in procedures such as peripheral vascular intervention, endovascular interventions, cardiac procedures, interventional radiology, venous procedures, and other end-user applications.

The respiratory endotherapy devices market consists of sales of bronchoscopes, endobronchial ultrasound systems, biopsy forceps, guidewires, catheters, airway stents, endobronchial valves, ablation devices, and related endoscopic and interventional pulmonology accessories. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.